Combination therapy
US9717778B2 · kind B2 · utility
2Cited by
1References
21Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 4, 2013 |
| Grant date | Aug 1, 2017 |
| Priority date | — |
| Expiry date | Feb 4, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.